In this podcast, Dr Aditya Bardia and Dr Virginia Kaklamani share their insights on the recent publication of the subgroup analyses from the phase 3 EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups.

Key topics include

• Identifying tumors that remain endocrine-sensitive despite acquired resistance to previous ET

• Clinical implications of the EMERALD post-hoc subgroup analyses

• Review of elacestrant's safety profile

Clinical takeaways

• Duration of prior ET + CDK4/6i ≥12 months was associated with a clinically meaningful improvement in PFS for elacestrant compared with SOC endocrine monotherapy in patients with ESR1-mut, ER+/HER2– metastatic breast cancer

• The PFS benefit associated with elacestrant was consistent across clinically relevant subgroups evaluated, including patients with bone metastases, liver and/or lung metastases, n<3 or ≥3 metastatic sites or tumors with PIK3CA-mut, TP53-mut, HER2-low tumor expression, or ESR1-mut variants D538G or Y537S/N

• Safety analyses demonstrated that elacestrant had a manageable safety profile similar to other ETs and without evidence of the toxicities associated with other drug classes, such as CDK4/6i and PI3K/AKT/mTOR inhibitors

• These data support current guidelines that recommend routine testing for the emergence of ESR1-mut in ctDNA at each disease progression

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.

This video was developed by https://cor2ed.com/

Published March 2025

This podcast explores the best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer.

Dr Rena Callahan and Dr Roberto Salgado discuss key biomarkers, testing methods, and clinical decision-making, offering expert insights on how to optimise precision medicine.

Topics include liquid vs. tumour biopsy, single gene vs. broad panel testing, and regional differences in testing practices.

Tune in for a practical, expert-led discussion on how molecular testing can guide personalised treatment and improve patient outcomes.

Key clinical takeaways:

• Molecular testing, especially for biomarkers like ESR1 and PI3 kinase, is a critical component in guiding treatment decisions, particularly in second-line therapy for HR+ HER2- metastatic breast cancer.

• Liquid biopsy is a valuable tool for ongoing monitoring of metastasis and detecting mutations like ESR1 during disease progression, but tissue biopsies may yield more reliable results for certain mutations like PI3 kinase alterations present early in cancer development.

• Testing for a broad range of mutations, such as PI3 kinase, AKT, PTEN, ESR1, MSI, and NTRK, allows for the identification of actionable mutations and eligibility for newer targeted therapies, especially in second and third-line treatments.

• Clinicians must be familiar with the specifics of the assays used to test for mutations, as different methods and testing conditions can impact results.

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/precision-oncology-connect/programmes/molecular-testing-targeted-therapy-metastatic-breast-cancer/?media=0

Or watch on YouTube: https://www.youtube.com/watch?v=CTnXmh1oDwQ

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/ntrk-connect/

X: https://x.com/PresOnc_Connect

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Thermo Fisher Scientific.

This podcast is developed by cor2ed.com

Published March 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions

Key clinical takeaways:

• MMR status should be tested in all patients at diagnosis and upon disease progression to guide personalised treatment decisions

• ICI and ChT combination, including with maintenance olaparib, demonstrates benefits in patients with non-dMMR advanced/recurrent endometrial cancer, with greater efficacy observed in dMMR populations

• Lenvatinib plus pembrolizumab is a viable option not only as 2nd line therapy but also as 1st line treatment for patients with non-dMMR advanced/recurrent endometrial cancer who have progressed after prior systemic therapy in any setting

• Shared decision-making, supported by patient education, is essential for optimising treatment outcomes

The treatment landscape for advanced and recurrent endometrial cancer (EC) is evolving, with molecular classification playing a key role in guiding decisions. In this podcast, Prof. Xavier Matias-Guiu (Pathologist) and Dr Jurjees Hasan (Medical Oncologist) discuss the latest advancements in personalised treatment approaches for EC.

Key topics include:

• The role of molecular classification in guiding treatment selection and testing strategies

• Treatment options for patients with pMMR status

• Effective patient communication for shared decision-making

Tune in for expert insights and practical guidance to optimise treatment strategies in advanced and recurrent EC

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/obstetrics-gynecology-connect/programmes/endometrial-cancer-molecular-classification-treatment-decisions/

Or watch on YouTube: https://youtu.be/KvYIB7PBpyQ

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/ob-gyn-connect/?viewAsMember=true

X: https://x.com/OBGynConnect

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this podcast.

This podcast is developed by cor2ed.com

Published February 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.